Publications

1. BMP7 Signaling in TGFBR2-deficient Stromal Cells Provokes Epithelial Carcinogenesis.Eikesdal HP, Becker LM, Teng Y, Kizu A, Carstens JL, Kanasaki K, Sugimoto H, LeBleu VS, Kalluri R.Mol Cancer Res. 2018 Jun 22. pii: molcanres.0120.2018. doi: 10.1158/1541-7786.MCR-18-0120.

2. Consensus guidelines for the use and interpretation of angiogenesis assays.Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW.Angiogenesis. 2018 May 15. doi: 10.1007/s10456-018-9613-x.

3. A peek into cancer-associated fibroblasts: origins, functions and translational impact.LeBleu VS, Kalluri R.Dis Model Mech. 2018 Apr 19;11(4). pii: dmm029447. doi: 10.1242/dmm.029447.

4. Generation and testing of clinical-grade exosomes for pancreatic cancer.Mendt M, Kamerkar S, Sugimoto H, McAndrews KM, Wu CC, Gagea M, Yang S, Blanko EVR, Peng Q, Ma X, Marszalek JR, Maitra A, Yee C, Rezvani K, Shpall E, LeBleu VS, Kalluri R.JCI Insight. 2018 Apr 19;3(8). pii: 99263. doi: 10.1172/jci.insight.99263.

5. Pharmacological induction of hypoxia-inducible transcription factor ARNT attenuates chronic kidney failure.Tampe B, Tampe D, Nyamsuren G, Klöpper F, Rapp G, Kauffels A, Lorf T, Zeisberg EM, Müller GA, Kalluri R, Hakroush S, Zeisberg M.J Clin Invest. 2018 Jun 11. pii: 89632. doi: 10.1172/JCI89632.

6. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes.Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, Wang F, Hawke D, Yu J, Healy LM, Hossain A, Akers JC, Maiti SN, Yamashita S, Shimizu Y, Dunner K, Zal MA, Burks JK, Gumin J, Nwajei F, Rezavanian A, Zhou S, Rao G, Sawaya R, Fuller GN, Huse JT, Antel JP, Li S, Cooper L, Sulman EP, Chen C, Geula C, Kalluri R, Zal T, Heimberger AB.Oncoimmunology. 2018 Jan 16;7(4):e1412909. doi: 10.1080/2162402X.2017.1412909. eCollection 2018.

7. The emerging roles of exosomes in the modulation of immune responses in cancer.Kurywchak P, Tavormina J, Kalluri R.Genome Med. 2018 Mar 26;10(1):23. doi: 10.1186/s13073-018-0535-4.

8. Fatty Acid Oxidation Regulates the Activation of Endothelial-to-Mesenchymal Transition.Lovisa S, Kalluri R.Trends Mol Med. 2018 May;24(5):432-434. doi: 10.1016/j.molmed.2018.03.003. Epub 2018 Mar 21.

9. EMT in cancer.Brabletz T, Kalluri R, Nieto MA, Weinberg RA.Nat Rev Cancer. 2018 Feb;18(2):128-134. doi: 10.1038/nrc.2017.118. Epub 2018 Jan 12. Review.

10. Depletion of S100A4+ stromal cells does not prevent HCC development but reduces the stem cell-like phenotype of the tumors.Jiao J, González Á, Stevenson HL, Gagea M, Sugimoto H, Kalluri R, Beretta L.Exp Mol Med. 2018 Jan 5;50(1):e422. doi: 10.1038/emm.2017.175.

11. Towards a joint reflection-distortion otoacoustic emission profile: Results in normal and impaired ears.Abdala C, Kalluri R.J Acoust Soc Am. 2017 Aug;142(2):812. doi: 10.1121/1.4996859.

12. Exosomes from Glioma-Associated Mesenchymal Stem Cells Increase the Tumorigenicity of Glioma Stem-like Cells via Transfer of miR-1587.Figueroa J, Phillips LM, Shahar T, Hossain A, Gumin J, Kim H, Bean AJ, Calin GA, Fueyo J, Walters ET, Kalluri R, Verhaak RG, Lang FF.Cancer Res. 2017 Nov 1;77(21):5808-5819. doi: 10.1158/0008-5472.CAN-16-2524. Epub 2017 Aug 30.

13. Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells.Pickup MW, Owens P, Gorska AE, Chytil A, Ye F, Shi C, Weaver VM, Kalluri R, Moses HL, Novitskiy SV.Cancer Immunol Res. 2017 Sep;5(9):718-729. doi: 10.1158/2326-6066.CIR-16-0311. Epub 2017 Aug 3.

14. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer.Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, Kalluri R.Nature. 2017 Jun 22;546(7659):498-503. doi: 10.1038/nature22341. Epub 2017 Jun 7.

15. An evolving function of DNA-containing exosomes in chemotherapy-induced immune response.Kurywchak P, Kalluri R.Cell Res. 2017 Jun;27(6):722-723. doi: 10.1038/cr.2017.74. Epub 2017 May 19.

16. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer.Carstens JL, Correa de Sampaio P, Yang D, Barua S, Wang H, Rao A, Allison JP, LeBleu VS, KalluriR.Nat Commun. 2017 Apr 27;8:15095. doi: 10.1038/ncomms15095.

17. Discovery of Double-Stranded Genomic DNA in Circulating Exosomes.Kalluri R, LeBleu VS.Cold Spring Harb Symp Quant Biol. 2016;81:275-280. doi: 10.1101/sqb.2016.81.030932. Epub 2017 Apr 19. Review.

18. Spatial Gradients in the Size of Inner Hair Cell Ribbons Emerge Before the Onset of Hearing in Rats.Kalluri R, Monges-Hernandez M.J Assoc Res Otolaryngol. 2017 Jun;18(3):399-413. doi: 10.1007/s10162-017-0620-1. Epub 2017 Mar 30.

19. Morphologically constrained spectral unmixing by dictionary learning for multiplex fluorescence microscopy.Megjhani M, Correa de Sampaio P, Leigh Carstens J, Kalluri R, Roysam B.Bioinformatics. 2017 Jul 15;33(14):2182-2190. doi: 10.1093/bioinformatics/btx108.

20. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.Yang S, Che SP, Kurywchak P, Tavormina JL, Gansmo LB, Correa de Sampaio P, Tachezy M, Bockhorn M, Gebauer F, Haltom AR, Melo SA, LeBleu VS, Kalluri R.Cancer Biol Ther. 2017 Mar 4;18(3):158-165. doi: 10.1080/15384047.2017.1281499. Epub 2017 Jan 25.

21. Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.Tampe B, Steinle U, Tampe D, Carstens JL, Korsten P, Zeisberg EM, Müller GA, Kalluri R, Zeisberg M.Kidney Int. 2017 Jan;91(1):157-176. doi: 10.1016/j.kint.2016.07.042. Epub 2016 Sep 28.

22. The biology and function of fibroblasts in cancer.Kalluri R.Nat Rev Cancer. 2016 Aug 23;16(9):582-98. doi: 10.1038/nrc.2016.73. Review.

23. Lovisa S, Zeisberg M, Kalluri R. Partial Epithelial-to-Mesenchymal Transition and Other New Mechanisms of Kidney Fibrosis. Trends Endocrinol Metab. Epub 6/2016. PMID: 27372267.

24. Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, LeBleu VS, Roy N, Novitskiy SV, Johansen JS, Poli V, Kalluri R, Iacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, Moses HL, Weaver VM. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med 22(5):497-505, 5/2016. Epub 4/2016. PMID: 27089513.

25. Kalluri R. The biology and function of exosomes in cancer. J Clin Invest 126(4):1208-15, 4/2016. Epub 4/2016. PMID: 270358122016.

26. Cleland TP, Schroeter ER, Zamdborg L, Zheng W, Lee JE, Tran JC, Bern M, Duncan MB, Lebleu VS, Ahlf DR, Thomas PM, Kalluri R, Kelleher NL, Schweitzer MH. Mass Spectrometry and Antibody-Based Characterization of Blood Vessels from Brachylophosaurus canadensis. J Proteome Res 14(12):5252-62, 12/2015. Epub 11/2015. PMID: 265955312015.

27. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS, Kalluri R. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527(7579):525-30. Epub 11/2015. PMID:26560028.

28. Lovisa S, LeBleu VS, Tampe B, Sugimoto H, Vadnagara K, Carstens JL, Wu CC, Hagos Y, Burckhardt BC, Pentcheva-Hoang T, Nischal H, Allison JP, Zeisberg M, Kalluri R. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med 21(9):998-1009, 9/2015. Epub 8/2015. PMID: 26236991.

29. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnica-Worms D, Kalluri R. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523 (7559): 177-82, 7/2015. Epub 6/2015. PMID: 26106858.

30. Léveillé N, Melo CA, Rooijers K, Díaz-Lagares A, Melo SA, Korkmaz G, Lopes R, Akbari Moqadam F, Maia AR, Wijchers PJ, Geeven G, den Boer ML, Kalluri R, de Laat W, Esteller M, Agami R. Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA. Nat Commun 6:6520, 3/2015. PMID: 25813522.

31. Zeisberg M, Kalluri R. Physiology of the Renal Interstitium. Clin J Am Soc Nephrol 10(10):1831-40, 10/2015. Epub 3/2015. PMID: 25813241.

32. Zhang J, Jiao J, Cermelli S, Muir K, Jung KH, Zou R, Rashid A, Gagea M, Zabludoff S, Kalluri R, Beretta L. miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells. Cancer Res 75(9):1859-67, 5/2015. Epub 3/2015. PMID: 25769721.

33. Tampe B, Tampe D, Zeisberg EM, Müller GA, Bechtel-Walz W, Koziolek M, Kalluri R, Zeisberg M. Induction of Tet3-dependent Epigenetic Remodeling by Low-dose Hydralazine Attenuates Progression of Chronic Kidney Disease. EBioMedicine 2(1):19-36, 1/2015. PMID: 25717475.

34. Keskin D, Kim J, Cooke VG, Wu CC, Sugimoto H, Gu C, De Palma M, Kalluri R, LeBleu VS. Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. Cell Rep 24;10(7):1066-81, 2/2015. Epub 2/2015. PMID: 25704811.

35. Xu X, Tan X, Tampe B, Nyamsuren G, Liu X, Maier LS, Sossalla S, Kalluri R, Zeisberg M, Hasenfuss G, Zeisberg EM. Epigenetic balance of aberrant Rasal1 promoter methylation and hydroxymethylation regulates cardiac fibrosis. Cardiovasc Res 1;105(3):279-91, 3/2015. Epub 1/2015. PMID: 25616414.

36. Xu X, Friehs I, Zhong Hu T, Melnychenko I, Tampe B, Alnour F, Iascone M, Kalluri R, Zeisberg M, Del Nido PJ, Zeisberg EM. Endocardial fibroelastosis is caused by aberrant endothelial to mesenchymal transition. Circ Res 116(5):857-66, 2/2015. Epub 1/2015. PMID: 25587097.

37. Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, Lucci A, Ivan C, Calin GA, Kalluri R. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 26(5):707-21, 11/2014. Epub 10/2014. PMID: 25446899.

38. Miyake T, Kalluri R. Cardiac biology: Cell plasticity helps hearts to repair. Nature 514(7524):575-6, 10/2014. Epub 10/2014. PMID: 25317554.

39. LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, de Carvalho FM, Damascena A, Domingos Chinen LT, Rocha RM, Asara JM, Kalluri R. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol 16(10):992-1003, 1-15, 10/2014. Epub 9/2014. Erratum in: Nat Cell Biol. 2014 Nov;16(11):1125. PMID: 25241037.

40. Zeisberg M, Tampe B, LeBleu V, Tampe D, Zeisberg EM, Kalluri R. Thrombospondin-1 deficiency causes a shift from fibroproliferative to inflammatory kidney disease and delays onset of renal failure. Am J Pathol 184(10):2687-98, 10/2014. Epub 8/2014. PMID: 25111226.

41. Charytan DM, Padera R, Helfand AM, Zeisberg M, Xu X, Liu X, Himmelfarb J, Cinelli A, Kalluri R, Zeisberg EM. Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease. Int J Cardiol 176(1):99-109, 9/2014. Epub 7/2014. PMID: 25049013.

42. Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25(6):719-34, 6/2014. Epub 5/2014. PMID: 24856586.

43. Ayala de la Peña F, Kanasaki K, Kanasaki M, Vong S, Rovira C, Kalluri R. Specific activation of K-RasG12D allele in the bladder urothelium results in lung alveolar and vascular defects. PLoS One 9(4):e95888, 4/2014. PMID: 24760005.

44. Carstens JL, Lovisa S, Kalluri R. Microenvironment-dependent cues trigger miRNA-regulated feedback loop to facilitate the EMT/MET switch. J Clin Invest 124(4):1458-60, 4/2014. Epub 3/2014. PMID: 24642461.

45. Tampe B, Tampe D, Müller CA, Sugimoto H, LeBleu V, Xu X, Müller GA, Zeisberg EM, Kalluri R, Zeisberg M. Tet3-mediated hydroxymethylation of epigenetically silenced genes contributes to bone morphogenic protein 7-induced reversal of kidney fibrosis. J Am Soc Nephrol 25(5):905-12, 5/2014. Epub 1/2014. PMID: 24480825.

24.

46. Kahlert C, Melo SA, Protopopov A, Tang J, Seth S, Koch M, Zhang J, Weitz J, Chin L, Futreal A,Kalluri R. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem 289(7):3869-75, 2/2014. Epub 1/2014. PMID: 24398677.

47. Sugimoto H, LeBleu VS, Bosukonda D, Keck P, Taduri G, Bechtel W, Okada H, Carlson W, Bey P, Rusckowski M, Tampe B, Tampe D, Kanasaki K, Zeisberg M, Kalluri R. Reply to Regarding the mechanism of action of a proposed peptide agonist of the bone morphogenetic protein receptor activin-like kinase 3. Nat Med 19(7):810-11, 7/2013. PMID: 23836214.

48. LeBleu VS, Taduri G, O'Connell J, Teng Y, Cooke VG, Woda C, Sugimoto H, Kalluri R. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 19(8):1047-53, 8/2013. Epub 6/2013. PMID: 23817022.

49. Plaks V, Rinkenberger J, Dai J, Flannery M, Sund M, Kanasaki K, Ni W, Kalluri R, Werb Z. Matrix metalloproteinase-9 deficiency phenocopies features of preeclampsia and intrauterine growth restriction. Proc Natl Acad Sci U S A 110(27):11109-14, 7/2013. Epub 6/2013. PMID: 23776237.

50. Duncan MB, Yang C, Tanjore H, Boyle PM, Keskin D, Sugimoto H, Zeisberg M, Olsen BR, Kalluri R. Type XVIII collagen is essential for survival during acute liver injury in mice. Dis Model Mech 6(4):942-51, 7/2013. Epub 4/2013. PMID: 23580202.

51. Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl). e-Pub 3/2013. PMID: 23519402.

52. Bronnum H, Andersen DC, Schneider M, Sandberg MB, Eskildsen T, Nielsen SB, Kalluri R, Sheikh SP. miR-21 Promotes Fibrogenic Epithelial-to-Mesenchymal Transition of Epicardial Mesothelial Cells Involving Programmed Cell Death 4 and Sprouty-1. PLoS One. E-Pub 2/2013. PMID: 23441172.

53. Kanasaki K, Yu W, von Bodungen M, Larigakis JD, Kanasaki M, Ayala de la Pena F, Kalluri R, Hill WG. Loss of β1-integrin from urothelium results in overactive bladder and incontinence in mice: a mechanosensory rather than structural phenotype. FASEB J. e-Pub 2/2013.

54. Lebleu VS, Teng Y, O'Connell JT, Charytan D, Müller GA, Müller CA, Sugimoto H, Kalluri R. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med 19(2):227-31, 2/2013. e-Pub 1/2013.

55. Melo SA, Kalluri R. miR-29b moulds the tumour microenvironment to repress metastasis. Nat Cell Biol 15(2):139-40, 12/2012.

56. Vong S, Kalluri R. The role of stromal myofibroblast and extracellular matrix in tumor angiogenesis. Genes Cancer. e-Pub 12/2012. PMID: 22866205.

57. Borges FT, Melo SA, Ozdemir BC, Kato N, Revuelta I, Miller CA, Gattone VH 2nd, Lebleu VS, Kalluri R. TGF-β1-Containing Exosomes from Injured Epithelial Cells Activate Fibroblasts to Initiate Tissue Regernative Responses and Fibrosis. J Am Soc Nephrol. e-Pub 12/2012. PMID: 23274427.

58. Medici D, Kalluri R. Endothelial-mesenchymal transition and its contribution to the emergence of stem cell phenotype. Semin Cancer Biol, 2012.

59. Melo CA, Drost J, Wijchers PJ, van de Werken H, de Wit E, Oude Vrielink JA, Elkon R, Melo SA, Léveillé N, Kalluri R, de Laat W, Agami R. eRNAs Are Required for p53-Dependent Enhancer Activity and Gene Transcription. Mol Cell 49(3):524-35, 2/2013. e-Pub 12/2012.

60. Zeisberg M, Kalluri R. Cellular Mechanisms of Tissue Fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol 304(3):C216-25, 2/2013. e-Pub 12/2012. PMCID: PMC3566435.

61. Kieran MW, Kalluri R, Cho YJ. The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med 2(12), 2012. e-Pub 12/2012.

62. Ho DN, Kohler N, Sigdel A, Kalluri R, Morgan JR, Xu C, Sun S. Penetration of endothelial cell coated multicellular tumor spheroids by iron oxide nanoparticles. Theranostics 2(1):66-75, 2012. e-Pub 1/2012. PMCID: PMC3263517.

63. Medici D, Kalluri R. Endothelial-mesenchymal transition and its contribution to the emergence of stem cell phenotype. Semin Cancer Biol 22(5-6):379-84, 2012.

64. Borges FT, Melo SA, Ozdemir BC, Kato N, Revuelta I, Miller CA, Gattone VH, Lebleu VS, Kalluri R. TGF-β1-Containing Exosomes from Injured Epithelial Cells Activate Fibroblasts to Initiate Tissue Regenerative Responses and Fibrosis. J Am Soc Nephrol. e-Pub 12/2012.

65. Medici D, Kalluri R. Endothelial-mesenchymal transition and its contribution to the emergence of stem cell phenotype. Semin Cancer Biol 22(5-6):379-84, 10/2012. e-Pub 4/2012. PMCID: PMC3422405.

66. Melo SA, Kalluri R. Molecular Pathways: MicroRNAs as Cancer Therapeutics. Clin Cancer Res 18(16):4234-9, 8/2012. e-Pub 6/2012.

67. Fan X, Li Q, Pisarek-Horowitz A, Rasouly HM, Wang X, Bonegio RG, Wang H, McLaughlin M, Mangos S, Kalluri R, Holzman LB, Drummond IA, Brown D, Salant DJ, Lu W. Inhibitory effects of Robo2 on nephrin: a crosswalk between positive and negative signals regulating podocyte structure. Cell Rep. e-Pub 7/2012. PMID: 22840396.

68. Melo SA, Kalluri R. Angiogenesis is controlled by miR-27b associated with endothelial tip cells. Blood 119(11):2439-40, 3/2012.

69. Sugimoto H, LeBleu VS, Bosukonda D, Keck P, Taduri G, Bechtel W, Okada H, Carlson W, Bey P, Rusckowski M, Tampe B, Tampe D, Kanasaki K, Zeisberg M, Kalluri R. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med 18(3):396-404, 3/2012. e-Pub 2/2012.

70. Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, Teng Y, Duncan MB, Xie L, Maeda G, Vong S, Sugimoto H, Rocha RM, Damascena A, Brentani RR, Kalluri R. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21(1):66-81, 1/2012.

71. Lebleu V, Kalluri R. Blocking PDGFR Signaling reduces Myofibroblasts and Attenuates Renal Fibrosis. Kidney Int 80(11):1119-21, 2011.

72. Tse JC, Kalluri R. Waking up dormant tumors. Breast Cancer Res 13(3):310, 2011.

73. Tse JC, Kalluri R. Waking up dormant tumors. Breast Cancer Res 13(3):310, 2011. e-Pub 6/2011. PMCID: PMC3218930.

74. Charytan DM, Helfand AM, MacDonald BA, Cinelli A, Kalluri R, Zeisberg EM. Circulating endoglin concentration is not elevated in chronic kidney disease. PLoS One 6(8):e23718, 2011. e-Pub 8/2011. PMCID: PMC3158786.

75. LeBleu VS, Kalluri R. Blockade of PDGF receptor signaling reduces myofibroblast number and attenuates renal fibrosis. Kidney Int 80(11):1119-21, 12/2011.

76. O'Connell JT, Sugimoto H, Cooke VG, MacDonald BA, Mehta AI, LeBleu VS, Dewar R, Rocha RM, Brentani RR, Resnick MB, Neilson EG, Zeisberg M, Kalluri R. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci U S A 108(38):16002-7, 9/2011. e-Pub 9/2011. PMCID: PMC3179047.

77. De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, Maertens O, Jeong SM, Bronson RT, Lebleu V, Kalluri R, Normant E, Haigis MC, Manning BD, Wong KK, Macleod KF, Cichowski K. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 20(3):400-13, 9/2011. PMCID: PMC3233475.

78. Medici D, Potenta S, Kalluri R. Transforming growth factor-β2 promotes Snail-mediated endothelial-mesenchymal transition through convergence of Smad-dependent and Smad-independent signalling. Biochem J 437(3):515-20, 8/2011.

79. Ayala de la Peña F, Kanasaki K, Kanasaki M, Tangirala N, Maeda G, Kalluri R. Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem 286(23):20778-87, 6/2011. e-Pub 3/2011. PMCID: PMC3121487.

80. Xie L, Duncan MB, Pahler J, Sugimoto H, Martino M, Lively J, Mundel T, Soubasakos M, Rubin K, Takeda T, Inoue M, Lawler J, Hynes RO, Hanahan D, Kalluri R. Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc Natl Acad Sci U S A 108(24):9939-44, 6/2011. e-Pub 5/2011. PMCID: PMC3116421.

81. Teng Y, Kanasaki K, Bardeesy N, Sugimoto H, Kalluri R. Deletion of Smad4 in fibroblasts leads to defective chondrocyte maturation and cartilage production in a TGFβ type II receptor independent manner. Biochem Biophys Res Commun 407(4):633-9, 4/2011. e-Pub 3/2011.

82. Melo S, Villanueva A, Moutinho C, Davalos V, Spizzo R, Ivan C, Rossi S, Setien F, Casanovas O, Simo-Riudalbas L, Carmona J, Carrere J, Vidal A, Aytes A, Puertas S, Ropero S, Kalluri R, Croce CM, Calin GA, Esteller M. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A 108(11):4394-9, 3/2011. e-Pub 2/2011. PMCID: PMC3060242.

83. Hertig A, Flier SN, Kalluri R. Contribution of epithelial plasticity to renal transplantation-associated fibrosis. Transplant Proc 42(Suppl 9):S7-12, 2010.

84. Nataraj D, Ernst A, Kalluri R. Idiopathic pulmonary fibrosis is associated with endothelial to mesenchymal transition. Am J Respir Cell Mol Biol 43(2):129-30, 2010.

85. Wiig H, Tenstad O, Iversen PO, Kalluri R, Bjerkvig R. Interstitial fluid: the overlooked component of the tumor microenvironment? Fibrogenesis Tissue Repair 23(3 (1)):12, 2010.

86. Wiig H, Keskin, D, Kalluri R. Lymphangiogenesis and the contribution of extracellular matrix. Matrix Biology, 2010.

87. Lee SB, Kalluri R. Mechanistic connection between inflammation and fibrosis. Kidney Int 78(Suppl 119):S22-6, 2010.

88. Keskin D, Kalluri R. NF-kappaB-induced chromatin remodeling regulates angiogenesis. Blood 116(3):312-3, 2010.

89. Zeisberg EM, Kalluri R. Origins of cardiac fibroblasts. Circ Res 107(11):1304-12, 2010.

90. Shenoy V, Kanasaki K, Kalluri R. Pre-eclampsia: connecting angiogenic and metabolic pathways. Trends Endocrinol Metab 21(9):529-36, 2010.

91. Shenoy V, Kanasaki K, Kalluri R. Pre-eclampsia: connecting angiogenic and metabolic pathways. Trends Endocrinol Metab 21(9):529-36, 2010.

92. Force T, Bonow RO, Houser SR, Solaro RJ, Hershberger RE, Adhikari B, Anderson ME, Boineau R, Byrne BJ, Cappola TP, Kalluri R, LeWinter MM, Maron MS, Molkentin JD, Ommen SR, Regnier M, Tang WH, Tian R, Konstam MA, Maron BJ, Seidman CE. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation 122(11):1130-3, 2010.

93. Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 225(3):631-7, 2010.

94. Polyak K, Kalluri R. The Role of the Microenvironment in Mammary Gland Development and Cancer. Cold Spring Harb Perspect Biol 2(11):a003244, 2010.

95. Bravo-Nuevo A, Sugimoto H, Iyer S, Fallon Z, Lucas JM, Kazerounian S, Prendergast GC, Kalluri R, Shapiro NI, Benjamin LE. RhoB loss prevents streptozotocin-induced diabetes and ameliorates diabetic complications in mice. Am J Pathol 178(1):245-52, 1/2011. e-Pub 12/2010. PMCID: PMC3069827.

96. Wiig H, Tenstad O, Iversen PO, Kalluri R, Bjerkvig R. Interstitial fluid: the overlooked component of the tumor microenvironment? Fibrogenesis Tissue Repair 3:12, 2010. e-Pub 7/2010. PMCID: PMC2920231.

97. Lee SB, Kalluri R. Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl(119):S22-6, 12/2010.

98. LeBleu V, Sund M, Sugimoto H, Birrane G, Kanasaki K, Finan E, Miller CA, Gattone VH, McLaughlin H, Shield CF, Kalluri R. Identification of the NC1 domain of {alpha}3 chain as critical for {alpha}3{alpha}4{alpha}5 type IV collagen network assembly. J Biol Chem 285(53):41874-85, 12/2010. e-Pub 9/2010. PMCID: PMC3009915.

99. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med 16(12):1400-6, 12/2010. e-Pub 11/2010. PMCID: PMC3209716.

100. Polyak K, Kalluri R. The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol 2(11):a003244, 11/2010. e-Pub 6/2010.

101. Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 225(3):631-7, 11/2010. PMCID: PMC3098503.

102. Zeisberg EM, Kalluri R. Origins of cardiac fibroblasts. Circ Res 107(11):1304-12, 11/2010. PMCID: PMC3098499.

103. Wiig H, Keskin D, Kalluri R. Interaction between the extracellular matrix and lymphatics: consequences for lymphangiogenesis and lymphatic function. Matrix Biol 29(8):645-56, 10/2010. e-Pub 8/2010.

104. Force T, Bonow RO, Houser SR, Solaro RJ, Hershberger RE, Adhikari B, Anderson ME, Boineau R, Byrne BJ, Cappola TP, Kalluri R, LeWinter MM, Maron MS, Molkentin JD, Ommen SR, Regnier M, Tang WH, Tian R, Konstam MA, Maron BJ, Seidman CE. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation 122(11):1130-3, 9/2010. PMCID: PMC3070356.

105. Shenoy V, Kanasaki K, Kalluri R. Pre-eclampsia: connecting angiogenic and metabolic pathways. Trends Endocrinol Metab 21(9):529-36, 9/2010. e-Pub 6/2010.

106. Hamano Y, Okude T, Shirai R, Sato I, Kimura R, Ogawa M, Ueda Y, Yokosuka O, Kalluri R, Ueda S. Lack of collagen XVIII/endostatin exacerbates immune-mediated glomerulonephritis. J Am Soc Nephrol 21(9):1445-55, 9/2010. e-Pub 7/2010. PMCID: PMC3013523.

107. Nataraj D, Ernst A, Kalluri R. Idiopathic pulmonary fibrosis is associated with endothelial to mesenchymal transition. Am J Respir Cell Mol Biol 43(2):129-30, 8/2010.

108. Keskin D, Kalluri R. NF-kappaB-induced chromatin remodeling regulates angiogenesis. Blood 116(3):312-3, 7/2010.

109. Flier SN, Tanjore H, Kokkotou EG, Sugimoto H, Zeisberg M, Kalluri R. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem 285(26):20202-12, 6/2010. e-Pub 4/2010. PMCID: PMC2888433.

110. Bechtel W, McGoohan S, Zeisberg EM, Müller GA, Kalbacher H, Salant DJ, Müller CA, Kalluri R, Zeisberg M. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 16(5):544-50, 5/2010. e-Pub 4/2010. PMCID: PMC3106179.

111. Hertig A, Gangadhar T, Kalluri R. Renal studies provide an insight into cardiac extracellular matrix remodeling during health and disease. J Mol Cell Cardiol 48(3):497-503, 3/2010. e-Pub 7/2009.

112. Lee SB, Wong AP, Kanasaki K, Xu Y, Shenoy VK, McElrath TF, Whitesides GM, Kalluri R. Preeclampsia: 2-methoxyestradiol induces cytotrophoblast invasion and vascular development specifically under hypoxic conditions. Am J Pathol 176(2):710-20, 2/2010. e-Pub 1/2010. PMCID: PMC2808078.

113. Lee SB, Kanasaki K, Kalluri R. Circulating TGF-beta1 as a reliable biomarker for chronic kidney disease progression in the African-American population. Kidney Int 76(1):10-2, 2009.

114. Ayala F, Dewar R, Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 23(12):2233-41, 2009.

115. Eikesdal HP, Kalluri R. Drug resistance associated with antiangiogenesis therapy. Semin Cancer Biol 19(5):310-7, 2009.

116. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 119(6):1417-9, 2009.

117. Kizu A, Medici D, Kalluri R. Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. Am J Pathol 175(4):1371-3, 2009.

118. Hertig A, Taduri G, Kalluri R. Insights to heart matrix remodeling is facilitated by the kidney. J Mol Cell Cardiology, 2009.

119. Duncan MB, Kalluri R. Parstatin, a novel protease-activated receptor 1-derived inhibitor of angiogenesis. Mol Interv 9(4):168-70, 2009.

120. Romagnani P, Kalluri R. Possible mechanisms of kidney repair. Fibrogenesis Tissue Repair 26(2(1)):3, 2009.

121. Kalluri R. Proteinuria With and Without Renal Glomerular Podocyte Effacement. J Am Soc Nephrol 17(9):2383-9, 2009.

122. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420-8, 2009.

123. Kanasaki K, Kalluri R. The Biology of Preeclampsia. Kidney Int 76(8):831-7, 2009.

124. Sund M, Kalluri R. Tumor Stroma Derived Biomarkers in Cancer. Cancer Metastasis Rev 28(1-2):177-83, 2009.

125. Romagnani P, Kalluri R. Possible mechanisms of kidney repair. Fibrogenesis Tissue Repair 2(1):3, 2009. e-Pub 6/2009. PMCID: PMC2711960.

126. LeBleu V, Sugimoto H, Mundel TM, Gerami-Naini B, Finan E, Miller CA, Gattone VH, Lu L, Shield CF, Folkman J, Kalluri R. Stem cell therapies benefit Alport syndrome. J Am Soc Nephrol 20(11):2359-70, 11/2009. e-Pub 10/2009. PMCID: PMC2799182.

127. Kanasaki K, Kalluri R. The biology of preeclampsia. Kidney Int 76(8):831-7, 10/2009. e-Pub 8/2009.

128. Kizu A, Medici D, Kalluri R. Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. Am J Pathol 175(4):1371-3, 10/2009. e-Pub 9/2009. PMCID: PMC2751533.

129. Eikesdal HP, Kalluri R. Drug resistance associated with antiangiogenesis therapy. Semin Cancer Biol 19(5):310-7, 10/2009. e-Pub 6/2009.

130. Duncan MB, Kalluri R. Parstatin, a novel protease-activated receptor 1-derived inhibitor of angiogenesis. Mol Interv 9(4):168-70, 8/2009. PMCID: PMC2863086.

131. Lee SB, Kanasaki K, Kalluri R. Circulating TGF-beta1 as a reliable biomarker for chronic kidney disease progression in the African-American population. Kidney Int 76(1):10-2, 7/2009.

132. Sund M, Kalluri R. Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev 28(1-2):177-83, 6/2009.

133. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420-8, 6/2009. PMCID: PMC2689101.

134. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 119(6):1417-9, 6/2009. PMCID: PMC2689122.

135. Sohn RL, Huang P, Kawahara G, Mitchell M, Guyon J, Kalluri R, Kunkel LM, Gussoni E. A role for nephrin, a renal protein, in vertebrate skeletal muscle cell fusion. Proc Natl Acad Sci U S A 106(23):9274-9, 6/2009. e-Pub 5/2009. PMCID: PMC2695070.

136. Chang SH, Kanasaki K, Gocheva V, Blum G, Harper J, Moses MA, Shih SC, Nagy JA, Joyce J, Bogyo M, Kalluri R, Dvorak HF. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res 69(10):4537-44, 5/2009. e-Pub 5/2009. PMCID: PMC2683911.

137. Schweitzer MH, Zheng W, Organ CL, Avci R, Suo Z, Freimark LM, Lebleu VS, Duncan MB, Vander Heiden MG, Neveu JM, Lane WS, Cottrell JS, Horner JR, Cantley LC, Kalluri R, Asara JM. Biomolecular characterization and protein sequences of the Campanian hadrosaur B. canadensis. Science 324(5927):626-31, 5/2009.

138. Nyberg P, Salo T, Kalluri R. Tumor microenvironment and angiogenesis. Front Biosci 13:6537-53, 2008. e-Pub 5/2008.

139. Cooke V, Kalluri R. Chapter 1 Molecular Mechanism of Type IV Collagen-Derived Endogenous Inhibitors of Angiogenesis. Methods Enzymol 444:1-19, 2008.

140. Zavadil J, Haley J, Kalluri R, Muthuswamy SK, Thompson E. Epithelial-mesenchymal Transition. Cancer Res 68(23):9574-7, 2008.

141. Kalluri R, Kanasaki K. RNA interference: generic block on angiogenesis. Nature 452(7187):543-5, 2008.

142. LeBleu VS, Kalluri R. Stem cell-based therapy for glomerular diseases: an evolving concept. J Am Soc Nephrol. 19(9):1621-3, 2008.

143. Potenta S, Zeisberg E, Kalluri R. The Role of Endothelial-to-Mesenchymal Transition in Cancer Progression. British Journal of Cancer 99(9):1375-9, 2008.

144. Zeisberg M, Kalluri R. Fibroblasts emerge via epithelial-mesenchymal transition in chronic kidney fibrosis. Front Biosci 13:6991-8, 2008. e-Pub 5/2008.

145. Cooke VG, Kalluri R. Chapter 1. Molecular mechanism of type IV collagen-derived endogenous inhibitors of angiogenesis. Methods Enzymol 444:1-19, 2008.

146. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 19(12):2282-7, 12/2008. e-Pub 11/2008. PMCID: PMC2588112.

147. Zavadil J, Haley J, Kalluri R, Muthuswamy SK, Thompson E. Epithelial-mesenchymal transition. Cancer Res 68(23):9574-7, 12/2008.

148. Nyberg P, Xie L, Sugimoto H, Colorado P, Sund M, Holthaus K, Sudhakar A, Salo T, Kalluri R. Characterization of the anti-angiogenic properties of arresten, an alpha1beta1 integrin-dependent collagen-derived tumor suppressor. Exp Cell Res 314(18):3292-305, 11/2008. e-Pub 8/2008. PMCID: PMC2613512.

149. LeBleu VS, Kalluri R. Stem cell-based therapy for glomerular diseases: an evolving concept. J Am Soc Nephrol 19(9):1621-3, 9/2008. e-Pub 8/2008.

150. Zeisberg M, Kalluri R. Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr Nephrol 23(9):1395-8, 9/2008. e-Pub 4/2008.

151. Eikesdal HP, Sugimoto H, Birrane G, Maeshima Y, Cooke VG, Kieran M, Kalluri R. Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity. Proc Natl Acad Sci U S A 105(39):15040-5, 9/2008. e-Pub 9/2008. PMCID: PMC2567489.

152. Kalluri R, Han Y. Targeting TGF-beta and the extracellular matrix in Marfan's syndrome. Dev Cell 15(1):1-2, 7/2008.

153. Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, Xie L, Parry S, Augustin HG, Gattone VH, Folkman J, Strauss JF, Kalluri R. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 453(7198):1117-21, 6/2008. e-Pub 5/2008.

154. Mundel TM, Yliniemi AM, Maeshima Y, Sugimoto H, Kieran M, Kalluri R. Type IV collagen alpha6 chain-derived noncollagenous domain 1 (alpha6(IV)NC1) inhibits angiogenesis and tumor growth. Int J Cancer 122(8):1738-44, 4/2008.

155. Kalluri R, Kanasaki K. RNA interference: generic block on angiogenesis. Nature 452(7187):543-5, 4/2008.

156. Lebleu VS, Sugimoto H, Miller CA, Gattone VH, Kalluri R. Lymphocytes are dispensable for glomerulonephritis but required for renal interstitial fibrosis in matrix defect-induced Alport renal disease. Lab Invest 88(3):284-92, 3/2008. e-Pub 1/2008.

157. Xie L, Palmsten K, MacDonald B, Kieran MW, Potenta S, Vong S, Kalluri R. Basement membrane derived fibulin-1 and fibulin-5 function as angiogenesis inhibitors and suppress tumor growth. Exp Biol Med (Maywood) 233(2):155-62, 2/2008.

158. Cosgrove D, Kalluri R, Miner JH, Segal Y, Borza DB. Choosing a mouse model to study the molecular pathobiology of Alport glomerulonephritis. Kidney Int 71(7):615-8, 2007.

159. Tse J, and Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J. Cell. Biochem 101(4):816-29, 2007.

160. LeBleu V, MacDonald M, Kalluri R. Structure and Function of Basement Membranes. Exp Biol Med 232(9):1121-9, 2007.

161. Teng Y, Zeisberg M, Kalluri R. Transcriptional regulation of epithelial-mesenchymal transition. J Clin Invest 117(2):304-306, 2007.

162. Mundel T, Kalluri R. Type IV collagen-derived Angiogenesis Inhibitors. Microvascular Research 74(2-3):85-89, 2007.

163. Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J. Modification of kidney barrier function by the urokinase receptor. Nat Med 14(1):55-63, 1/2008. e-Pub 12/2007.

164. Kanasaki K, Kanda Y, Palmsten K, Tanjore H, Lee SB, Lebleu VS, Gattone VH, Kalluri R. Integrin beta1-mediated matrix assembly and signaling are critical for the normal development and function of the kidney glomerulus. Dev Biol 313(2):584-93, 1/2008. e-Pub 11/2007.

165. Tanjore H, Zeisberg EM, Gerami-Naini B, Kalluri R. Beta1 integrin expression on endothelial cells is required for angiogenesis but not for vasculogenesis. Dev Dyn 237(1):75-82, 1/2008.

166. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67(21):10123-8, 11/2007.

167. LeBleu VS, Macdonald B, Kalluri R. Structure and function of basement membranes. Exp Biol Med (Maywood) 232(9):1121-9, 10/2007.

168. Mundel TM, Kalluri R. Type IV collagen-derived angiogenesis inhibitors. Microvasc Res 74(2-3):85-9, Sep-Nov, 9/2007. e-Pub 5/2007.

169. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, Kalluri R. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282(32):23337-47, 8/2007. e-Pub 6/2007.

170. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13(8):952-61, 8/2007. e-Pub 7/2007.

171. Sugimoto H, Grahovac G, Zeisberg M, Kalluri R. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 56(7):1825-33, 7/2007. e-Pub 4/2007.

172. Tse JC, Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101(4):816-29, 7/2007.

173. Garovic VD, Wagner SJ, Petrovic LM, Gray CE, Hall P, Sugimoto H, Kalluri R, Grande JP. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 22(4):1136-43, 4/2007. e-Pub 1/2007.

174. Teng Y, Zeisberg M, Kalluri R. Transcriptional regulation of epithelial-mesenchymal transition. J Clin Invest 117(2):304-6, 2/2007. PMCID: PMC1783811.

175. Kalluri R, Zeisberg E. Controlling Angiogenesis in Heart Valves. Nat Med 12:1118-1119, 2006.

176. Kalluri R, Zeisberg M. Fibroblasts in Cancer. Nature Rev Cancer 6(5):392-401, 2006.

177. Lee J, Dedhar S, Kalluri R, Thompson E. The Epithelial-Mesenchymal Transition: New Insights in Signalling, Development and Disease. J. Cell Bio 172(7):973-81, 2006.

178. Tanjore H, Kalluri R. The Role of Type IV Collagen and Basement Membranes in Cancer Progression and Metastasis. Am J Pathol 168(3):715-7, 2006.

179. Sugimoto H, Yang C, LeBleu VS, Soubasakos MA, Giraldo M, Zeisberg M, Kalluri R. BMP-7 functions as a novel hormone to facilitate liver regeneration. FASEB J 21(1):256-64, 1/2007. e-Pub 11/2006.

180. Hahm K, Lukashev ME, Luo Y, Yang WJ, Dolinski BM, Weinreb PH, Simon KJ, Chun Wang L, Leone DR, Lobb RR, McCrann DJ, Allaire NE, Horan GS, Fogo A, Kalluri R, Shield CF, Sheppard D, Gardner HA, Violette SM. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol 170(1):110-25, 1/2007. PMCID: PMC1762706.

181. Dandapani SV, Sugimoto H, Matthews BD, Kolb RJ, Sinha S, Gerszten RE, Zhou J, Ingber DE, Kalluri R, Pollak MR. Alpha-actinin-4 is required for normal podocyte adhesion. J Biol Chem 282(1):467-77, 1/2007. e-Pub 11/2006.

182. Sugimoto H, Mundel TM, Kieran MW, Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5(12):1640-6, 12/2006. e-Pub 12/2006.

183. Kalluri R, Zeisberg E. Controlling angiogenesis in heart valves. Nat Med 12(10):1118-9, 10/2006.

184. Kalluri R. Proteinuria with and without renal glomerular podocyte effacement. J Am Soc Nephrol 17(9):2383-9, 9/2006. e-Pub 8/2006.

185. Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res 66(13):6622-7, 7/2006.

186. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 6(5):392-401, 5/2006.

187. Sugimoto H, Mundel TM, Sund M, Xie L, Cosgrove D, Kalluri R. Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci U S A 103(19):7321-6, 5/2006. e-Pub 4/2006. PMCID: PMC1464339.

188. Zeisberg M, Khurana M, Rao VH, Cosgrove D, Rougier JP, Werner MC, Shield CF, Werb Z, Kalluri R. Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med 3(4):e100, 4/2006. e-Pub 3/2006. PMCID: PMC1391977.

189. MacDonald BA, Sund M, Grant MA, Pfaff KL, Holthaus K, Zon LI, Kalluri R. Zebrafish to humans: evolution of the alpha3-chain of type IV collagen and emergence of the autoimmune epitopes associated with Goodpasture syndrome. Blood 107(5):1908-15, 3/2006. e-Pub 10/2005. PMCID: PMC1895704.

190. Tanjore H, Kalluri R. The role of type IV collagen and basement membranes in cancer progression and metastasis. Am J Pathol 168(3):715-7, 3/2006. PMCID: PMC1606530.

191. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172(7):973-81, 3/2006. PMCID: PMC2063755.

192. Zeisberg M, Kramer K, Sindhi N, Sarkar P, Upton M, Kalluri R. De-differentiation of primary human hepatocytes depends on the composition of specialized liver basement membrane. Mol Cell Biochem 283(1-2):181-9, 2/2006.

193. Zeisberg M, Kalluri R. Animal Models for Renal Fibrosis. Methods Mol Med 117:261-72, 2005.

194. Okada H, and Kalluri R. Cellular and Molecular Pathways that Lead to Progression and Regression of Renal Fibrogenesis. Curr Mol Med 5:467-74, 2005.

195. Nyberg P, Xie L, Kalluri R. Endogenous Inhibitors of Angiogenesis. Cancer Research 65:10, 2005.

196. Okada H, Kalluri R. Recapitulation of kidney development paradigms by BMP-7 reverses chronic renal injury. Clin Exp Nephrol 9:100-1, 2005.

197. Kalluri R, Grant MA. Structure-Function Analysis of Endogenous Inhibitors of Angiogenesis. Cold Spring Harbor Symposia on Controlling Cancer 70:1-12, 2005.

198. Hamano Y, Kalluri R. Tumstatin as an Angiogenesis Inhibitor and Tumor Suppressor. Biochem Biophys Res Commun. 333:292-98, 2005.

199. Wang B, Sun J, Kitamoto S, Yang M, Grubb A, Chapman HA, Kalluri R, Shi GP. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 281(9):6020-9, 3/2006. e-Pub 12/2005.

200. Sund M, Zeisberg M, Kalluri R. Invited Review: Endogenous stimulators and inhibitors of angiogenesis in gastrointestinal cancers: basic science to clinical application. Gastroenterology 129(6):2076-91, 2005.

201. Zeisberg M, Soubasakos MA, Kalluri R. Animal models of renal fibrosis. Methods Mol Med 117:261-72, 2005.

202. Sund M, Zeisberg M, Kalluri R. Endogenous stimulators and inhibitors of angiogenesis in gastrointestinal cancers: basic science to clinical application. Gastroenterology 129(6):2076-91, 12/2005.

203. Zehnder AF, Adams JC, Santi PA, Kristiansen AG, Wacharasindhu C, Mann S, Kalluri R, Gregory MC, Kashtan CE, Merchant SN. Distribution of type IV collagen in the cochlea in Alport syndrome. Arch Otolaryngol Head Neck Surg 131(11):1007-13, 11/2005.

204. Sudhakar A, Nyberg P, Keshamouni VG, Mannam AP, Li J, Sugimoto H, Cosgrove D, Kalluri R. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J Clin Invest 115(10):2801-10, 10/2005. e-Pub 9/2005. PMCID: PMC1199529.

205. Hamano Y, Kalluri R. Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem Biophys Res Commun 333(2):292-8, 7/2005.

206. Reiser J, Polu KR, Möller CC, Kenlan P, Altintas MM, Wei C, Faul C, Herbert S, Villegas I, Avila-Casado C, McGee M, Sugimoto H, Brown D, Kalluri R, Mundel P, Smith PL, Clapham DE, Pollak MR. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 37(7):739-44, 7/2005. e-Pub 5/2005. PMCID: PMC1360984.

207. Okada H, Kalluri R. Recapitulation of kidney development paradigms by BMP-7 reverses chronic renal injury. Clin Exp Nephrol 9(2):100-1, 6/2005.

208. Reynolds J, Prodromidi EI, Juggapah JK, Abbott DS, Holthaus KA, Kalluri R, Pusey CD. Nasal administration of recombinant rat alpha3(IV)NC1 prevents the development of experimental autoimmune glomerulonephritis in the WKY rat. J Am Soc Nephrol 16(5):1350-9, 5/2005. e-Pub 4/2005.

209. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 65(10):3967-79, 5/2005.

210. Sund M, Maeshima Y, Kalluri R. Bifunctional promoter of type IV collagen COL4A5 and COL4A6 genes regulates the expression of alpha5 and alpha6 chains in a distinct cell-specific fashion. Biochem J 387(Pt 3):755-61, 5/2005. PMCID: PMC1135006.

211. Charytan D, MacDonald B, Sugimoto H, Pastan S, Staton G, Hennigar R, Kalluri R. An unusual case of pulmonary-renal syndrome associated with defects in type IV collagen composition and anti-glomerular basement membrane autoantibodies. Am J Kidney Dis 45(4):743-8, 4/2005.

212. Zeisberg M, Shah AA, Kalluri R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem 280(9):8094-100, 3/2005. e-Pub 12/2004.

213. Krishna TH, Mahipal S, Sudhakar A, Sugimoto H, Kalluri R, Rao KS. Reduced DNA gap repair in aging rat neuronal extracts and its restoration by DNA polymerase beta and DNA-ligase. J Neurochem 92(4):818-23, 2/2005.

214. Zeisberg M, Müller G, Kalluri R. Are there endogenous molecules that protect kidneys from injury? The case for bone morphogenic protein-7 (BMP-7). Nephrology Dialysis Transplantation 19:759-61, 2004.

215. Folkman J, Kalluri R. Cancer without Disease. Nature 427:785, 2004.

216. Zeisberg M, Kalluri R. Experimental strategies to reverse chronic renal failure. Blood Purification 22:440-5, 2004.

217. Sund M, Xie L, Kalluri R. The contribution of vascular basement membranes and extracellular matrix in the mechanics of tumor angiogenesis. APMIS 112:450-62, 2004.

218. Zeisberg M, Kalluri R. The Role of Epithelial-to Mesenchymal-Transition in Renal Fibrosis. J Mol Med 82:175-81, 2004.

219. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, Benjamin LE, Lawler J, Kieran M, Shah A, Kalluri R. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A 102(8):2934-9, 2/2005. e-Pub 2/2005. PMCID: PMC549486.

220. Zeisberg M, Kalluri R. Experimental strategies to reverse chronic renal disease. Blood Purif 22(5):440-5, 2004. e-Pub 9/2004.

221. Sund M, Xie L, Kalluri R. The contribution of vascular basement membranes and extracellular matrix to the mechanics of tumor angiogenesis. APMIS 112(7-8):450-62, Jul-Aug, 7/2004.

222. Benigni A, Gagliardini E, Tomasoni S, Abbate M, Ruggenenti P, Kalluri R, Remuzzi G. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 65(6):2193-200, 6/2004.

223. Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, Rastaldi MP, Calvaresi N, Watanabe H, Schwarz K, Faul C, Kretzler M, Davidson A, Sugimoto H, Kalluri R, Sharpe AH, Kreidberg JA, Mundel P. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 113(10):1390-7, 5/2004. PMCID: PMC406528.

224. Charytan D, Torre A, Khurana M, Nicastri A, Stillman IE, Kalluri R. Allograft rejection and glomerular basement membrane antibodies in Alport's syndrome. J Nephrol 17(3):431-5, May-Jun, 5/2004.

225. Zeisberg M, Müller GA, Kalluri R. Are there endogenous molecules that protect kidneys from injury? The case for bone morphogenic protein-7 (BMP-7). Nephrol Dial Transplant 19(4):759-61, 4/2004.

226. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, Kalluri R. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64(5):1570-4, 3/2004.

227. Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med (Berl) 82(3):175-81, 3/2004. e-Pub 1/2004.

228. Folkman J, Kalluri R. Cancer without disease. Nature 427(6977):787, 2/2004.

229. Bhattacharya G, Kalluri R, Orten DJ, Kimberling WJ, Cosgrove D. A domain-specific usherin/collagen IV interaction may be required for stable integration into the basement membrane superstructure. J Cell Sci 117(Pt 2):233-42, 1/2004.

230. Kalluri R. Basement membranes: structural features, assembly, cellular interactions and role in cancer angiogenesis. Nature Rev Cancer 3(6):422-33, 2003.

231. Kalluri R, Neilson E. G. Epithelial to Mesenchymal Transition and its Implication for Fibrosis. J Clin Invest. 112:1776-1784, 2003.

232. Kalluri R, Zeisberg M. Exploring the connection between chronic renal fibrosis and bone morphogenic protein-7. Histology and Histopathology 18(1):217-24, 2003.

233. Yang C, Zeisberg M, Lively JC, Nyberg P, Afdhal N, Kalluri R. Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res 63(23):8312-7, 12/2003.

234. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112(12):1776-84, 12/2003. PMCID: PMC297008.

235. Zeisberg M, Bottiglio C, Kumar N, Maeshima Y, Strutz F, Müller GA, Kalluri R. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol 285(6):F1060-7, 12/2003. e-Pub 8/2003.

236. Salama AD, Chaudhry AN, Holthaus KA, Mosley K, Kalluri R, Sayegh MH, Lechler RI, Pusey CD, Lightstone L. Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. Kidney Int 64(5):1685-94, 11/2003.

237. Charytan DM, Le DD, Grossman JM, Holthaus KA, Kalluri R. Antiglomerular basement membrane autoantibodies are nonpathogenic in Wegener's granulomatosis. Am J Med 115(5):414-5, 10/2003.

238. Gagliardini E, Benigni A, Tomasoni S, Abbate M, Kalluri R, Remuzzi G. Targeted downregulation of extracellular nephrin in human IgA nephropathy. Am J Nephrol 23(4):277-86, Jul-Aug, 7/2003. e-Pub 7/2003.

239. McDonald GA, Sarkar P, Rennke H, Unemori E, Kalluri R, Sukhatme VP. Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo. Am J Physiol Renal Physiol 285(1):F59-67, 7/2003.

240. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9(7):964-8, 7/2003.

241. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A, Kalluri R. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 3(6):589-601, 6/2003. PMCID: PMC2775452.

242. Kos CH, Le TC, Sinha S, Henderson JM, Kim SH, Sugimoto H, Kalluri R, Gerszten RE, Pollak MR. Mice deficient in alpha-actinin-4 have severe glomerular disease. J Clin Invest 111(11):1683-90, 6/2003. PMCID: PMC156110.

243. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3(6):422-33, 6/2003.

244. Hopfer H, Maron R, Butzmann U, Helmchen U, Weiner HL, Kalluri R. The importance of cell-mediated immunity in the course and severity of autoimmune anti-glomerular basement membrane disease in mice. FASEB J 17(8):860-8, 5/2003.

245. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278(15):12605-8, 4/2003. e-Pub 1/2003.

246. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A 100(8):4766-71, 4/2003. e-Pub 4/2003. PMCID: PMC153630.

247. Yang C, Zeisberg M, Mosterman B, Sudhakar A, Yerramalla U, Holthaus K, Xu L, Eng F, Afdhal N, Kalluri R. Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology 124(1):147-59, 1/2003.

248. Kalluri R. Discovery of Type IV Collagen Non-collagenous Domains as Novel Integrin Ligands and Endogenous Inhibitors of Angiogenesis. Cold Spring Harb Symp Quant Biol 67:255-66, 2002.

249. Tsukaguchi H, Sudhakar A, Le TC, Nguyen T, Yao J, Schwimmer JA, Schachter AD, Poch E, Abreu PF, Appel GB, Pereira AB, Kalluri R, Pollak MR. NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest 110(11):1659-66, 12/2002. PMCID: PMC151634.

250. Iglesias-de la Cruz MC, Ziyadeh FN, Isono M, Kouahou M, Han DC, Kalluri R, Mundel P, Chen S. Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 62(3):901-13, 9/2002.

251. Bloom RD, O'Connor T, Cizman B, Kalluri R, Naji A, Madaio MP. Intrathymic kidney cells delay the onset of lupus nephritis in MRL-lpr/lpr mice. Int Immunol 14(8):867-71, 8/2002.

252. Hamano Y, Grunkemeyer JA, Sudhakar A, Zeisberg M, Cosgrove D, Morello R, Lee B, Sugimoto H, Kalluri R. Determinants of vascular permeability in the kidney glomerulus. J Biol Chem 277(34):31154-62, 8/2002. e-Pub 5/2002.

253. Natoli TA, Liu J, Eremina V, Hodgens K, Li C, Hamano Y, Mundel P, Kalluri R, Miner JH, Quaggin SE, Kreidberg JA. A mutant form of the Wilms' tumor suppressor gene WT1 observed in Denys-Drash syndrome interferes with glomerular capillary development. J Am Soc Nephrol 13(8):2058-67, 8/2002.

254. Zeisberg M, Ericksen MB, Hamano Y, Neilson EG, Ziyadeh F, Kalluri R. Differential expression of type IV collagen isoforms in rat glomerular endothelial and mesangial cells. Biochem Biophys Res Commun 295(2):401-7, 7/2002.

255. Zeisberg M, Maeshima Y, Mosterman B, Kalluri R. Renal fibrosis. Extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells. Am J Pathol 160(6):2001-8, 6/2002. PMCID: PMC1850832.

256. Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Müller GA, Neilson EG. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int 61(5):1714-28, 5/2002.

257. Meyers KE, Allen J, Gehret J, Jacobovits A, Gallo M, Neilson EG, Hopfer H, Kalluri R, Madaio MP. Human antiglomerular basement membrane autoantibody disease in XenoMouse II. Kidney Int 61(5):1666-73, 5/2002.

258. Reimer CL, Agata N, Tammam JG, Bamberg M, Dickerson WM, Kamphaus GD, Rook SL, Milhollen M, Fram R, Kalluri R, Kufe D, Kharbanda S. Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. Cancer Res 62(3):789-95, 2/2002.

259. Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR, Sonenberg N, Hynes RO, Kalluri R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295(5552):140-3, 1/2002.

260. Zeisberg M, Bonner G, Maeshima Y, Colorado P, Muller GA, Strutz F, Kalluri R. Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol 159(4):1313-21, 2001.

261. Okada H, Inoue T, Kanno Y, Kobayashi T, Ban S, Kalluri R, Suzuki H. Renal fibroblast-like cells in Goodpasture syndrome rats. Kidney Int 60(2):597-606, 2001.

262. Maeshima Y, Manfredi M, Reimer C, Holthaus KA, Hopfer H, Chandamuri BR, Kharbanda S, Kalluri R. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem 276(18):15240-8, 2001.

263. Maeshima Y, Yerramalla UL, Dhanabal M, Holthaus KA, Barbashov S, Kharbanda S, Reimer C, Manfredi M, Dickerson WM, Kalluri R. Extracellular matrix-derived peptide binds to αVβ3 integrin and inhibits angiogenesis. J Biol Chem 276(34):31959-68, 2001.

264. Karumanchi SA, Jha V, Ramchandran R, Karihaloo A, Tsiokas L, Chan B, Dhanabal M, Hanai JI, Venkataraman G, Shriver Z, Keiser N, Kalluri R, Zeng H, Mukhopadhyay D, Chen RL, Lander AD, Hagihara K, Yamaguchi Y, Sasisekharan R, Cantley L, Sukhatme VP. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 7(4):811-22, 2001.

265. Benigni A, Tomasoni S, Gagliardini E, Zoja C, Grunkemeyer JA, Kalluri R, Remuzzi G. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol 12(5):941-8, 2001.

245. 216. Chugh S, Yuan H, Topham PS, Haydar SA, Mittal V, Taylor GA, Kalluri R, Salant DJ. Aminopeptidase A: a nephritogenic target antigen of nephrotoxic serum. Kidney Int 59(2):601-13, 2001.

266. Kalluri R, Sukhatme VP. Fibrosis & angiogenesis. Curr Opin Nephrol Hypertens 9(4):413-8, 2000.

267. Maeshima Y, Colorado PC, Kalluri R. Two RGD-independent αvβ3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 275(31):23745-50, 2000.

268. Kalluri R, Cantley LG, Kerjaschki D, Neilson EG. Reactive oxygen species expose cryptic epitopes associated with autoimmune Goodpasture syndrome. J Biol Chem 275(26):20027-32, 2000.

269. Okada H, Moriwaki K, Kalluri R, Takenaka T, Imai H, Ban S, Takahama M, Suzuki H. Osteopontin expressed by renal tubular epithelium mediates interstitial monocyte infiltration in rats. Am J Physiol Renal Physiol 278(1):F110-21, 2000.

270. Salloum RM, Jaskowiak NT, Mauceri HJ, Seetharam S, Beckett MA, Koons AM, Hari DM, Gupta VK, Reimer C, Kalluri R, Posner MC, Hellman S, Kufe DW, Weichselbaum RR. NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity. Cancer Res 60(24):6958-63, 2000.

271. Cosgrove D, Rodgers K, Meehan D, Miller C, Bovard K, Gilroy A, Gardner H, Kotelianski V, Gotwals P, Amatucci A, Kalluri R. Integrin α1β1 and transforming growth factor-β1 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol 157(5):1649-59, 2000.

272. Okada H, Moriwaki K, Kalluri R, Imai H, Ban S, Takahama M, Suzuki H. Inhibition of monocyte chemoattractant protein-1 expression in tubular epithelium attenuates tubulointerstitial alteration in rat Goodpasture syndrome. Kidney Int 57(3):927-36, 2000.

273. Kalluri R, Torre A, Shield CF III, Zamborsky ED, Werner MC, Suchin E, Wolf G, Helmchen UM, vd Heuvel L, Grossman R, Aradhye S, Neilson EG. Identification of α3, α4 and α5 chains of type IV collagen as alloantigens for Alport posttransplant anti-glomerular basement membrane antibodies. Transplantation 69(4):679-83, 2000.

274. Rutgers A, Meyers KE, Canziani G, Kalluri R, Lin J, Madaio MP. High affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients α3(IV)NC1 collagen. Kidney Int 58(1):115-22, 2000.

275. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, Hopfer H, Xiao Y, Stillman IE, Kalluri R. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 275(28):21340-8, 2000.

276. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme, VP, Kalluri R. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 275(2):1209-15, 2000.

277. Kalluri R, Cosgrove D. Assembly of type IV collagen. Insights from α3(IV) collagen-deficient mice. J Biol Chem 275(17):12719-24, 2000.

278. Hanna NN, Seetharam S, Mauceri HJ, Beckett MA, Jaskowiak NT, Salloum RM, Hari D, Dhanabal M, Ramchandran R, Kalluri R, Sukhatme VP, Kufe DW, Weichselbaum RR. Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J 6(5):287-93, 2000.

279. Colorado PC, Torre A, Kamphaus G, Maeshima Y, Hopfer H, Takahashi K, Volk R, Zamborsky ED, Herman S, Sarkar PK, Ericksen MB, Dhanabal M, Simons M, Post M, Kufe DW, Weichselbaum RR, Sukhatme VP, Kalluri R. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 60(9):2520-6, 2000.

280. Kalluri R. Goodpasture Syndrome. Kidney Int 55(3):1120-22, 1999.

281. Sayers R, Kalluri R, Rodgers KD, Shield CF, Meehan DT, Cosgrove D. Role for transforming growth factor-β1 in Alport renal disease progression. Kidney Int 56(5):1662-73, 1999.

282. Lei H, Kalluri R, Furth EE, Baker AH, Strauss JF III. Rat amnion type IV collagen composition and metabolism: implications for membrane breakdown. Biol Reprod 60(1):176-82, 1999.

283. Lei H, Furth EE, Kalluri R, Wakenell P, Kallen CB, Jeffrey JJ, Leboy PS, Strauss JF III. Induction of matrix metalloproteinases and collagenolysis in chick embryonic membranes before hatching. Biol Reprod 60(1):183-9, 1999.

284. Van Vliet AI, Van Alderwegen IE, Baelde HJ, de Heer E, Killen PD, Kalluri R, Bruijn JA, Bergijk EC. Differential expression of collagen type IV α-chains in the tubulointerstitial compartment in experimental chronic serum sickness nephritis. J Pathol 189(2):279-87, 1999.

285. Wolf G, Kalluri R, Ziyadeh FN, Neilson EG, Stahl RA. Angiotensin II induces α3(IV) collagen expression in cultured murine proximal tubular cells. Proc Assoc Am Phys 111(4):357-64, 1999.

286. Kalluri R, Gattone VH, Hudson BG. Identification and localization of type IV collagen chains in the inner ear cochlea. Connect Tissue Res 37(1-2):143-50, 1998.

287. Meyers KE, Kinniry PA, Kalluri R, Neilson EG, Madaio MP. Human Goodpasture anti-α3(IV) NC1 autoantibodies share structural determinants. Kidney Int 2(402-7), 53, 1998.

288. Abbate M, Kalluri R, Corna D, Yamaguchi N, McCluskey RT, Hudson BG, Andres G, Zoja C, Remuzzi G. Experimental Goodpasture’s syndrome in Wistar-Kyoto rats immunized with α-3 chain of type IV collagen. Kidney Int 54(5):1550-61, 1998.

289. Bergijk EC, Van Alderwegen IE, Baelde HJ, de Heer E, Funabiki K, Miyai H, Killen PD, Kalluri R, Bruijn JA. Differential expression of collagen IV isoforms in experimental glomerulosclerosis. J Pathol 184(3):307-15, 1998.

290. Minto AW, Kalluri R, Togawa M, Bergijk EC, Killen PD, Salant DJ. Augmented expression of glomerular basement membrane specific type IV collagen isoforms (α3-α5) in experimental membranous nephropathy. Proc Assoc Am Phys 110(3):207-17, 1998.

291. Ziyadeh FN, Mogyorosi A, Kalluri R. Early and advanced non-enzymatic glycation products in the pathogenesis of diabetic kidney disease. Exp Nephrol 5(1):2-9, 1997.

292. Tuori AJ, Virtanen I, Aine E, Kalluri R, Miner JH, Uusitalo HM. The immunohistochemical composition of corneal basement membrane in keratoconus. Curr Eye Res 16(8):792-801, 1997.

293. Kalluri R, Danoff TM, Okada H, Neilson EG. Susceptibility to anti-glomerular basement membrane disease and Goodpasture syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice. J Clin Invest 100(9):2263-75, 1997.

294. Vargas MT, Gustilo K, D’Andrea DM, Kalluri R, Foster MH, Madaio MP. Structural features of nephritogenic lupus autoantibodies. Methods 11(1):62-9, 1997.

295. Kahsai TZ, Enders GC, Gunwar S, Brunmark C, Wieslander J, Kalluri R, Zhou J, Noelken ME, Hudson BG. Seminiferous tubule basement membrane. Composition and organization of type IV collagen chains, and the linkage of α3(IV) and α5(IV) chains. J Biol Chem 272(27):17023-32, 1997.

296. Kalluri R, Shield CF, Todd P, Hudson BG, Neilson EG. Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 99(10):2470-8, 1997.

297. Kalluri R, Meyers K, Mogyorosi A, Madaio MP, Neilson EG. Goodpasture syndrome involving overlap with Wegener’s granulomatosis and anti-glomerular basement membrane disease. J Am Soc Nephrol 8(11):1795-800, 1997.

298. Lohi J, Korhonen M, Leivo I, Kangas L, Tani T, Kalluri R, Miner JH, Lehto VP, Virtanen I. Expression of type IV collagen α1(IV)- α6(IV) polypeptides in normal and developing human kidney and in renal cell carcinomas and oncocytomas. Int J Cancer 72(1):43-9, 1997.

299. Okada H, Danoff TM, Kalluri R, Neilson EG. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 273(4 Part 2):F563-74, 1997.

300. D’Andrea D, Meyers K, Kalluri R, Madaio MP. Glomerular and renal parenchymal diseases. Curr Nephrol 20:179-208, 1996.

301. Okada H, Strutz F, Danoff TD, Kalluri R, Neilson EG. Possible mechanisms of renal fibrosis. Contrib Nephrol 118:147-54, 1996.

303. Kalluri R, Sun MJ, Hudson BG, Neilson EG. The Goodpasture autoantigen. Structural delineation of two immunologically privileged epitopes on α3(IV) chain of type IV collagen. J Biol Chem 271(15):9062-8, 1996.

304. Kalluri R, Melendez E, Rumpf KW, Sattler K, Muller GA, Strutz F, Neilson EG. Specificity of circulating and tissue-bound autoantibodies in Goodpasture syndrome. Proc Am Assoc Phys 108(2):134-9, 1996.

305. Ortiz-Arduan A, Danoff TM, Kalluri R, Gonzalez-Cuadrado S, Karp SL, Elkon K, Egido J, Neilson EG. Regulation of Fas and Fas ligand expression in cultured murine renal cells and in the kidney during endotoxemia. Am J Physiol 271(6 (Pt 2)):F1193-201, 1996.

306. Boutaud AA, Kalluri R, Kahsai TZ, Noelken ME, Hudson BG. Goodpasture syndrome: selective removal of anti-α3 (IV) collagen autoantibodies. A potential therapeutic alternative to plasmapheresis. Exp Nephrol 4(4):205-12, 1996.

307. Thorner PS, Zheng K, Kalluri R, Jacobs R, Hudson BG. Coordinate gene expression of the α3, α4, and α5 chains of collagen type IV. Evidence from a canine model of X-linked nephritis with a COL4A5 gene mutation. J Biol Chem 271(23):13821-8, 1996.

308. Merkel F, Kalluri R, Marx M, Enders U, Stevanovic S, Giegerich G, Neilson EG, Rammensee HG, Hudson BG, Weber M. Autoreactive T-cells in Goodpasture’s syndrome recognize the N-terminal NC1 domain on α3 type IV collagen. Kidney Int 49(4):1127-33, 1996.

309. Kalluri R, Petrides S, Wilson CB, Tomaszewski JE, Palevsky HI, Grippi MA, Madaio MP, Neilson EG. Anti-α(IV) collagen autoantibodies associated with lung adenocarcinoma presenting as the Goodpasture syndrome. Ann Intern Med 124(7):651-3, 1996.

310. Lei H, Furth EE, Kalluri R, Chiou T, Tilly KI, Tilly JL, Elkon KB, Jeffrey JJ, Strauss JF III. A program of cell death and extracellular matrix degradation is activated in the amnion before the onset of labor. J Clin Invest 98(9):1971-8, 1996.

311. Kalluri R, Wilson CB, Weber M, Gunwar S, Chinko AM, Neilson EG, Hudson BG. Identification of the a3 chain of type IV collagen as the common autoantigen in anti-basement membrane disease and Goodpasture syndrome. J Am Soc Nephrol 6(4):1178-85, 1995.

312. Peissel B, Geng L, Kalluri R, Kashtan C, Rennke HG, Gallo GR, Yoshioka K, Sun MJ, Hudson BG, Neilson EG, Zhou J. Comparative distribution of the α1(IV), α5(IV), and α6(IV) collagen chains in normal human adult and fetal tissues and in kidneys from X-linked Alport syndrome patients. J Clin Invest 96(4):1948-57, 1995.

313. Kalluri R, vd Heuvel L, Smeets HJ, Schroder CH, Lemmink HH, Boutaud A, Neilson EG, Hudson BG. COL4a3 gene mutation and post-ttransplant anti-a3 (IV) collagen alloantibodies in Alport syndrome. Kidney Int 47(4):1199-204, 1995.

314. Hudson BG, Kalluri R, Tryggvason K. Pathology of glomerular basement membrane nephropathy. Curr Opin Nephrol Hypertens 3(3):334-9, 1994.

315. Hudson BG, Kalluri R, Gunwar S, Noelken ME. Structure and organization of type IV collagen of renal glomerular basement membrane. Contrib nephrol 107:163-7, 1994.

316. Noelken ME, Reddy GK, Kalluri R, Gunwar S, Hudson BG. The chain composition of aorta basement membrane collagen IV, localization of the chains in aorta and supramolecular assembly of the collagen IV protomers. Contrib Nephrol 107:216-9, 1994.

317. Kalluri R, Gattone VH, Noelken ME, Hudson BG. The a3 chain of type (IV) collagen induces autoimmune Goodpasture sydrome. Proc Natl Acad Sci U S A 91(13):6201-5, 1994.

318. Kalluri R, Weber M, Netzer KO, Sun MJ, Neilson EG, Hudson BG. COL4A5 gene deletion and production of post-transplant anti-alpha 3 (IV) collagen alloantibodies in Alport syndrome. Kidney Int 45(3):721-6, 1994.

319. Ding J, Kashtan CE, Fan WW, Kleppel MM, Sun MJ, Kalluri R, Neilson EG, Michael AF. A monoclonal antibody marker for Alport syndrome identifies the Alport antigen as the a5 chain of type IV collagen. Kidney Int 45(5):1504-6, 1994.

320. Hudson BG, Kalluri R, Gunwar S, Noelken ME, Mariyama M, Reeders ST. Molecular characteristics of Goodpasture autoantigen. Kidney Int 43(1):135-9, 1993.

321. Reddy GK, Gunwar S, Kalluri R, Hudson BG, Noelken ME. Structure and composition of type IV collagen of bovine aorta. Biochem Biophys Acta 1157(3):241-51, 1993.

322. Neilson EG, Kalluri R, Sun MJ, Gunwar S, Danoff T, Mariyama M, Myers JC, Reeders ST, Hudson BG. Specificity of Goodpasture autoantibodies for the recombinant noncollagenous domains of human type IV collagen. J Biol Chem 268(12):8402-5, 1993.

323. Hudson BG, Kalluri R, Gunwar S, Weber M, ballester F, Hudson JK, Noelken ME, Sarras M, Richardson WR, Saus J, Abrahamson DR, GLick AD, Haralson MA, Helderman JH, Stone WJ, Jacobson HR. The pathogenesis of Alport syndrome involves type IV collagen molecules containing the a3(IV) chain: evidence from anti-GBM nephritis after renal transplantation. Kidney Int 42(1):179-87, 1992.

324. Mariyama M, Kalluri R, Hudson BG, Reeders St. The a4(IV) chain of basement membrane collagen: Isolation of cDNAs encoding bovine a4(IV) and comparison with other type IV collagens. J Biol Chem 267(2):1253-8, 1992.

325. Kalluri R, Gunwar S, Reeders ST, Morrison KC, Mariyama M, Ebner KE, Noelken ME, Hudson BG. Goodpasture Syndrome. Localization of the epitope for the autoantibodies to the carboxyl-terminal region of the a3(IV) chain of basement membrane collagen. J Biol Chem 266(35):24018-24, 1991.

326. Gunwar S, Ballester F, Kaluri R, Timoneda J, Chonko AM, Edwards SJ, Noelken ME, Hudson BG. Glomerular basement membrane. Identification of dimeric subunits of the noncollagenous domain (hexamer) of collagen IV and the Goodpasture antigen. J Biol Chem 266(23):15318-24, 1991.

327. Gunwar S, Bejarano PA, Kalluri R, Langeveld JP, Wisdom BJ Jr, Noelken ME, Hudson BG. Alveolar basement membrane:molecular properties of the noncollagenous domain (hexamer) of collagen IV and its reactivity with Goodpasture autoantibodies. Am J Respir Cell Mol Biol 5(2):107-12, 1991.